This module enables investors to look at Blueprint Medicines various fundamental indicators over time in order to gain insight into the company future performance. Macroaxis historical fundamental analysis tools allow evaluation of not only typical financial statement drivers such as Gross Profit of 21.4 M, Interest Expense of 818.8 K or Operating Expenses of 74.2 M, but also many exotic indicators such as Long Term Debt to Equity of 0.0608, Revenue to Assets of 0.075 or Total Assets Per Share of 7.7762. This module is a perfect complement to use when analyzing Blueprint Medicines Valuation or Volatility. It can also complement various Blueprint Medicines Technical models. Check also analysis of Blueprint Medicines Correlation with competitors.